Vaccine News and Research

RSS

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

New DNA analysis leads to first accurate tuberculosis genome identification

A novel genome assembly tool that has been created by researchers could lead to the creation of fresh antibiotics for the bacterial infections that cause tuberculosis and other diseases.

From Rutgers University 20 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Small fluorescent protein helps researchers to capture deeper, more precise biomedical images

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.

7 Dec 2022

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

AI creates artificial DNA to control cell protein production

Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.

25 Nov 2022

Chemically attenuated live DNA virus vaccine prevents viral infection

Rutgers researchers have devised a new way to prevent viral infections: a live-attenuated, replication-defective DNA virus vaccine that utilizes the substance centanamycin to create an altered virus for vaccine development.

From Rutgers University 22 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

Recognizing how the HIV-1 evades immune system

According to a recent study led by Andrés Finzi, a professor at the Université de Montréal and researcher at the CHUM Research Centre, the type of virus used as a model to study the effectiveness of non-neutralizing antibodies against the virus that causes AIDS, has a crucial role to play.

10 Nov 2022

Understanding immune cell function to improve vaccine efficacy

The immune system’s capacity to remember defeated disease-causing germs and avoid recurrent infections is still poorly understood, but a new study published in Science Immunology fills in some gaps.

From Rutgers University 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Novel liposomal nanovaccines strongly activate cellular immunity

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.

2 Nov 2022

Genetic timestamping tracks the fate of plasma cells over time

Vaccines function by effectively producing immune cells that live for a long time, frequently for decades. These immune cells form a protective barrier that prevents or reduces re-infection, as well as a memory that enables one to identify an old invader, such as a virus, and eliminate it before it causes disease.

1 Nov 2022

Resistance against Epstein-Barr virus from experimental monoclonal antibodies

When tested in a lab setting using human cells, a panel of experimental monoclonal antibodies (mAbs) that target various Epstein-Barr virus (EBV) sites prevented infection.

1 Nov 2022

Highly effective and safe Zika vaccine technology

Scientists from the University of California, Los Angeles (UCLA) have discovered a Zika vaccine technology that is very safe and effective in preclinical mouse models.

29 Sep 2022

Novel means to prevent and treat gonorrhea

According to scientists from the Georgia State University’s Institute for Biomedical Sciences, producing a mutation that impedes the way the bacterial pathogen Neisseria gonorrhoeae transmits gonorrhea might provide a novel means to prevent and treat the disease.

26 Sep 2022

MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

12 Sep 2022

Therapeutic mRNAs do not significantly impact translational fidelity

Synthetic mRNA therapeutics for the treatment and prevention of disease has attracted a lot of interest due to the exceptional efficacy of mRNA vaccinations against SARS-CoV-2.

30 Aug 2022

Unconventional T cells migrate and influence immune responses

There are 600 to 800 lymph nodes in the human body, which are specialized organs that cause immunological reactions. Lymph nodes are connected to the various organs by lymph vessels, allowing them to receive information about infections in the body.

25 Aug 2022